An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer. - Wikidata - wikimedia - TriplyDB

An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer.

An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer.

http://www.wikidata.org/entity/Q34214898

about

The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study.Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.Prior administration of a non-steroidal anti-androgen failed to prevent the flare-up caused by a luteinizing hormone-releasing hormone agonist in a patient with metastatic prostate cancer.Degarelix for the treatment of advanced prostate cancer compared with GnRh-Agonists: a systematic review and meta-analysis.Clinical significance of suboptimal hormonal levels in men with prostate cancer treated with LHRH agonists Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments.Androgen deprivation therapy: past, present and future.Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy.New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.Autophagy in prostate cancer and androgen suppression therapy.Degarelix: a review of its use in patients with prostate cancer.Pharmacokinetic and pharmacodynamic profile of degarelix for prostate cancer.Overview of elagolix for the treatment of endometriosis.Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts.An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer.Effect of Degarelix, a Gonadotropin-Releasing Hormone Receptor Antagonist for the Treatment of Prostate Cancer, on Cardiac Repolarisation in a Randomised, Placebo and Active Comparator Controlled Thorough QT/QTc Trial in Healthy Men.Experience with degarelix in the treatment of prostate cancer.Re: 'Use of androgen deprivation therapy in prostate cancer: indications and prevalence' by Connolly et al.Gonadotropin-releasing hormone receptor-targeted paclitaxel-degarelix conjugate: synthesis and in vitro evaluation.Degarelix treatment is compatible with diabetes and antithrombotic therapy in patients with prostate cancer.Therapeutic outcomes of the LHRH antagonists.

P2860

Q28072710-66DA9BCE-A452-4AD5-9E8B-E53C8AAE7CB7 Q33647728-D083EDFC-4FDA-42AC-92EA-E0E359DA2FB5 Q34636636-8AA889ED-76DA-47C5-92FC-64469A91FBD8 Q35737858-7E554732-FA6B-4087-BDEF-99939D1F483D Q36070721-0C442C39-7FB8-4DBE-8D51-1196CA390641 Q36833751-373F6D2F-0880-4674-87CA-C827BDA3AA27 Q37947081-5AC5C62D-949B-436E-9CC9-701E42CC7E07 Q38016530-5D4919A6-F359-433B-A223-CAF707725985 Q38016531-F183B67F-B758-4868-9EAC-84235CECA515 Q38023124-407443F9-8C3C-4FB7-8E51-9A77B579BBAE Q38112596-DC3AB0EF-AE77-4EBB-9DCD-87B36802DAFD Q38206404-294F9482-BBF2-4BED-8EB1-D074256D3BAD Q38619233-5C1BF566-4B9F-46BF-8015-26A44941C325 Q38791644-F158D015-22A2-4531-91C9-B1CD0B1B3BD7 Q38798811-95A15E91-08AA-4334-B200-9AFEDEDCE50F Q39236911-69835698-2920-4EF2-AF2F-6CF3E499C0B5 Q40018470-C20BC3F7-D35B-461D-80F9-342514EE6BE6 Q41508156-C6E8E530-43E7-4525-ABE7-9D25BCFEBBA9 Q42029952-5AA37CE1-22C8-4DC6-97E5-77DA34B5B2EB Q42540042-2C96A111-B587-4024-B3F5-96E968842726 Q42828662-44E406F0-B281-471D-961B-3F2E5F759998 Q47148733-C159E5A2-3361-49A5-AF04-BFAA3D6DFC1C Q47859553-C5FCB6C3-5127-4563-876A-E6CA2D442DCA

P2860

An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer.

http://www.wikidata.org/entity/Q34214898

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer.

@ast

An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer.

@en

An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer.

@nl

type

label

An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer.

@ast

An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer.

@en

An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer.

@nl

prefLabel

An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer.

@ast

An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer.

@en

An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer.

@nl

P1433

Q34214898-22AE0B0C-6E18-4292-80DA-BA0C704486BC

P1476

Q34214898-C3D392AA-0DAA-4154-AED9-D7AF975B5379

P2093

Q34214898-41410FD6-77C3-4DA0-9177-5F0586AB24B2

Q34214898-B5206AA2-133C-4C3C-B645-4578967A92B9

Q34214898-D8561EA1-73B9-4C16-85D4-C26D2BA1AFD6

P2860

Q34214898-13B4BE29-BC0B-4E98-BB79-BFF570F991C5

Q34214898-1A39009B-D989-4D57-89D5-BE22F8BF0E6C

Q34214898-22BEFA84-CA80-40D1-87C8-596242515185

Q34214898-2A675B9F-191E-4A25-81B7-FE46D3BE6780

Q34214898-342954CA-0E57-498D-989F-992D3FDB3DF1

Q34214898-37986493-67CE-4755-B208-14E199484E1E

Q34214898-3E4BA0B9-781C-421C-AB77-CCC96759731E

Q34214898-4C95411C-E5DB-4561-9EDD-9D56BA01E8EB

Q34214898-4DABB72C-1408-4C82-A564-CC144B56AA73

Q34214898-52445092-68C8-42BD-BD6C-DE749623D01E

P304

Q34214898-EC49DDA0-C311-4043-9D49-AA89E5121548

P31

Q34214898-33E6A490-5C5F-4663-A62C-7528AA09C9A3

P356

Q34214898-1439370E-0A18-4758-952B-4256960E8997

P433

Q34214898-13AB4D78-D481-4397-B73E-0A87BA654A81

P478

Q34214898-67C38BDF-DB69-4463-94E7-AF8E2D3DC3AC

P577

Q34214898-DE194DE5-2DAE-401A-B58A-764D956DE151

P5875

Q34214898-A9694320-BE09-474C-AD6A-5AF15B57BA0D

P698

Q34214898-4094274D-06FC-4400-9A42-1B1AE1B753D8

P932

Q34214898-BBF61F86-C5A8-41CF-BFFB-6F9FA7B146B9

P356

1756287211414457

P1433

Therapeutic advances in urology

P1476

An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer.

@en

P2093

Bo-Eric Persson

http://www.w3.org/2001/XMLSchema#string

Egbert van der Meulen

http://www.w3.org/2001/XMLSchema#string

Laurent Boccon-Gibod

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications.

Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer.

The LHRH antagonist cetrorelix: a review.

Gonadotropin-releasing-hormone-receptor antagonists.

Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.

Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study.

Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer

Prediction of survival of metastatic prostate cancer based on early serial measurements of prostate specific antigen and alkaline phosphatase.

Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer.

P304

127-140

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1756287211414457

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51636174

http://www.w3.org/2001/XMLSchema#string

P698

21904569

http://www.w3.org/2001/XMLSchema#string

P932

3159401

http://www.w3.org/2001/XMLSchema#string